These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37975597)

  • 1. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
    Padhani ZA; Gangwani MK; Sadaf A; Hasan B; Colan S; Alvi N; Das JK
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD011626. PubMed ID: 37975597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
    Sadaf A; Hasan B; Das JK; Colan S; Alvi N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD011626. PubMed ID: 29998494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for osteoporosis in people with beta-thalassaemia.
    Bhardwaj A; Swe KMM; Sinha NK
    Cochrane Database Syst Rev; 2023 May; 5(5):CD010429. PubMed ID: 37159055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
    Gupta V; Kumar I; Raj V; Aggarwal P; Agrawal V
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29564. PubMed ID: 35092347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Geneen LJ; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
    Foong WC; Loh CK; Ho JJ; Lau DS
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013767. PubMed ID: 36637054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone therapy for people with thalassaemia.
    Ngim CF; Lai NM; Hong JY; Tan SL; Ramadas A; Muthukumarasamy P; Thong MK
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012284. PubMed ID: 32463488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.
    Shakoor A; Zahoor M; Sadaf A; Alvi N; Fadoo Z; Rizvi A; Quadri F; Tipoo FA; Khurshid M; Sajjad Z; Colan S; Hasan BS
    BMJ Open; 2014 Dec; 4(12):e005360. PubMed ID: 25492271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major.
    Khaled A; Salem HA; Ezzat DA; Seif HM; Rabee H
    Drug Des Devel Ther; 2019; 13():2427-2436. PubMed ID: 31413542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy for late-onset Pompe disease.
    Dalmia S; Sharma R; Ramaswami U; Hughes D; Jahnke N; Cole D; Smith S; Remmington T
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD012993. PubMed ID: 38084761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive treatment for kidney transplant recipients.
    Natale P; Mooi PK; Palmer SC; Cross NB; Cooper TE; Webster AC; Masson P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2024 Jul; 7(7):CD003598. PubMed ID: 39082471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone therapy for people with thalassaemia.
    Ngim CF; Lai NM; Hong JY; Tan SL; Ramadas A; Muthukumarasamy P; Thong MK
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012284. PubMed ID: 28921500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line diuretics versus other classes of antihypertensive drugs for hypertension.
    Reinhart M; Puil L; Salzwedel DM; Wright JM
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD008161. PubMed ID: 37439548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.